Development of a Standardized Reference Guide for Tuning Adherence to Dispense During a Initial Pharmaceutical Consulting (CP ) to the Patient With Multiple Myeloma Oral Chemotherapy Primocure

Multiple Myeloma Clinical Trial

Official title:

Elaboration of a Standardized Referential Guide of the Information to Optimize the Adherence to be Given During an Initial Pharmaceutical Consultation (CP) to the Patient Suffering From Multiple Myeloma in Primocure Chemotherapy Per os

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04045561
• Other study ID #: LOCAL/2015/MF-01
• Status: Completed
• Start date: June 1, 2015
• Est. completion date: December 31, 2016

Study information

• Verified date: July 2019
• Source: Centre Hospitalier Universitaire de Nimes
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The hypothesis is that the implementation of an initial Pharmaceutical Consultation (PC) program based on the provision of standardized information to patients treated for multiple myeloma as a first course of chemotherapy, could optimize their compliance with the delivered per os treatment.

The aim of this study is therefore to develop a standardised reference guide of information to be provided during prostate cancer in order to optimise the compliance of patients treated for multiple myeloma as a first course of chemotherapy per os.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: December 31, 2016
• Est. primary completion date: December 31, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria

• The patient must be a member or beneficiary of a health insurance plan

• The patient is at least 18 years old

• The patient is treated for multiple myeloma, is naive to any treatment and begins a chemotherapy protocol with oral therapy and whose course of care includes a stay in the Day Hospital or retrocessions.

Criteria for non-inclusion

• The subject is participating in another study

• The subject is in an exclusion period determined by a previous study

• The subject is under the protection of justice, guardianship or curatorship

• It is impossible to give informed information about

• The patient is pregnant, parturient, or breastfeeding

• The patient receives a follow-up by a home nurse for the administration of oral medication

• The patient is treated only with oral chemotherapy in the city

• The patient has early dementia.

Translated with www.DeepL.com/Translator

-

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nimes

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	evaluating the understanding	Questionnaire. quantitative variables: measurement of the mean and standard deviation or by their median and quartiles according to their distribution.	Day 1
Primary	evaluating understanding	Questionnaire. qualitative variables: measurement of their number and	Day 1
Primary	evaluating the quality of information	Questionnaire. quantitative variables: measurement of the mean and standard deviation or by their median and quartiles according to their distribution.	Day 1
Primary	evaluating quality of information	Questionnaire. qualitative variables: measurement of their number and percentage.	Day 1
Secondary	The time required for the pharmaceutical consultation	minutes	Day 1
Secondary	satisfaction des patients	by an Analogue Visual Scale (0-10-very satisfied)	Day 1